JP2016515517A - 徐放性ミクロスフェア及びその製造方法 - Google Patents

徐放性ミクロスフェア及びその製造方法 Download PDF

Info

Publication number
JP2016515517A
JP2016515517A JP2016502862A JP2016502862A JP2016515517A JP 2016515517 A JP2016515517 A JP 2016515517A JP 2016502862 A JP2016502862 A JP 2016502862A JP 2016502862 A JP2016502862 A JP 2016502862A JP 2016515517 A JP2016515517 A JP 2016515517A
Authority
JP
Japan
Prior art keywords
active ingredient
physiologically active
dispersed phase
solvent
betamethasone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016515517A5 (enExample
Inventor
リッチー，トレイシー
タノー，バガバシカヌン，チサンバラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016515517A publication Critical patent/JP2016515517A/ja
Publication of JP2016515517A5 publication Critical patent/JP2016515517A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
JP2016502862A 2013-03-15 2014-03-14 徐放性ミクロスフェア及びその製造方法 Pending JP2016515517A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361790554P 2013-03-15 2013-03-15
US61/790,554 2013-03-15
PCT/US2014/028657 WO2014144309A1 (en) 2013-03-15 2014-03-14 Sustained release microspheres and method of producing the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019080106A Division JP6808777B2 (ja) 2013-03-15 2019-04-19 徐放性ミクロスフェア及びその製造方法

Publications (2)

Publication Number Publication Date
JP2016515517A true JP2016515517A (ja) 2016-05-30
JP2016515517A5 JP2016515517A5 (enExample) 2018-11-22

Family

ID=51537672

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502862A Pending JP2016515517A (ja) 2013-03-15 2014-03-14 徐放性ミクロスフェア及びその製造方法
JP2019080106A Active JP6808777B2 (ja) 2013-03-15 2019-04-19 徐放性ミクロスフェア及びその製造方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019080106A Active JP6808777B2 (ja) 2013-03-15 2019-04-19 徐放性ミクロスフェア及びその製造方法

Country Status (8)

Country Link
US (1) US9956177B2 (enExample)
EP (1) EP2968184B1 (enExample)
JP (2) JP2016515517A (enExample)
CN (1) CN105705141B (enExample)
CA (1) CA2909303C (enExample)
ES (1) ES2697696T3 (enExample)
MX (1) MX362187B (enExample)
WO (1) WO2014144309A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020202831A1 (enExample) * 2019-03-29 2020-10-08
JP2023551508A (ja) * 2020-11-30 2023-12-08 エルジー・ケム・リミテッド カスパーゼ阻害剤を含有する注射用組成物及びその製造方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9956177B2 (en) 2013-03-15 2018-05-01 Oakwood Laboratories LLC Sustained release microspheres and method of producing same
EP4297753A4 (en) 2021-02-24 2025-01-01 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
US20240148662A1 (en) * 2021-03-11 2024-05-09 Oakwood Laboratories, Llc Methods and systems for making polymer microspheres
CN116999412A (zh) * 2023-08-03 2023-11-07 四川迈可隆生物科技有限公司 一种含有倍他米松药物的缓释微球制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356419A (ja) * 2001-03-29 2002-12-13 Takeda Chem Ind Ltd 微粒薬物の製造法
WO2012112747A2 (en) * 2011-02-16 2012-08-23 Oakwood Laboratories, Llc Manufacture of microspheres using a hydrocyclone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
WO2002078673A1 (fr) * 2001-03-29 2002-10-10 Takeda Chemical Industries, Ltd. Procede de production d'un medicament sous forme de granules fins
WO2005107714A2 (en) * 2004-05-05 2005-11-17 Alkermes Controlled Therapeutics, Inc. Method of forming microparticles that include a bisphosphonate and a polymer
GB2461186B (en) 2008-04-21 2010-09-01 Otonomy Inc Controlled release corticosteroid compositions and methods for the treatment of otic disorders
US20100086596A1 (en) * 2008-10-06 2010-04-08 Oakwood Laboratories LLC Microspheres for releasing an octreotide compound without an initial time lag
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
UA111162C2 (uk) * 2010-08-04 2016-04-11 Флекшен Терап'Ютікс, Інк. Ін'єкційна композиція ацетоніду триамцинолону для лікування болю
US9956177B2 (en) 2013-03-15 2018-05-01 Oakwood Laboratories LLC Sustained release microspheres and method of producing same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356419A (ja) * 2001-03-29 2002-12-13 Takeda Chem Ind Ltd 微粒薬物の製造法
WO2012112747A2 (en) * 2011-02-16 2012-08-23 Oakwood Laboratories, Llc Manufacture of microspheres using a hydrocyclone

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020202831A1 (enExample) * 2019-03-29 2020-10-08
JP7576334B2 (ja) 2019-03-29 2024-10-31 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
JP2023551508A (ja) * 2020-11-30 2023-12-08 エルジー・ケム・リミテッド カスパーゼ阻害剤を含有する注射用組成物及びその製造方法

Also Published As

Publication number Publication date
JP6808777B2 (ja) 2021-01-06
CN105705141A (zh) 2016-06-22
CN105705141B (zh) 2018-12-28
MX362187B (es) 2019-01-08
ES2697696T3 (es) 2019-01-25
US20160030351A1 (en) 2016-02-04
CA2909303C (en) 2021-10-19
EP2968184A1 (en) 2016-01-20
MX2015012231A (es) 2016-05-05
EP2968184B1 (en) 2018-10-24
JP2019112471A (ja) 2019-07-11
WO2014144309A1 (en) 2014-09-18
BR112015022524A2 (pt) 2017-08-22
CA2909303A1 (en) 2014-09-18
EP2968184A4 (en) 2016-09-07
US9956177B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
JP6808777B2 (ja) 徐放性ミクロスフェア及びその製造方法
JP6678571B2 (ja) 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法
KR102752744B1 (ko) 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법
RU2013109362A (ru) Кортикостероиды для лечения суставной боли
JP6722828B2 (ja) フィナステリドを含むマイクロ粒子及びその製造方法
EP0625069A1 (de) Verfahren zur herstellung von mikrokapseln
DE69715191T2 (de) Verfahren zur Herstellung von Mikropartikeln
WO2023015851A1 (zh) 一种注射用曲安奈德微球植入剂及其制备方法
US9636308B2 (en) High drug load buprenorphine microspheres and method of producing same
CN110381924A (zh) 包含莫西菌素的微粒及其制备方法
CN105169366B (zh) 一种醋酸曲普瑞林缓释微球的制备方法
JP2016515517A5 (enExample)
CN108295045B (zh) 一种液晶凝胶微囊及其制备方法
KR20190121699A (ko) 데옥시콜린산을 포함하는 피하 주사용 조성물 및 이의 제조 방법
CN101485904A (zh) 含载药可注射硫酸钙基缓释植入组份及应用
CN120267621A (zh) 一种多奈哌齐缓释制剂及其制备方法
JP2023538901A (ja) ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
EP4031108B1 (de) Extrudierte depotform mit kontrollierter wirkstofffreisetzung
CN117731643A (zh) 一种曲安奈德缓释微球、无菌制备方法及缓释制剂
BR112015022524B1 (pt) Método de produção de uma formulação de microesferas de liberação sustentada e formulação de liberação sustentada
KR102700719B1 (ko) 덱사메타손 아세테이트를 포함하는 서방형 주사제제 및 그 제조방법
KR102715550B1 (ko) 유효성분을 함유하는 왁스 파티클 및 이의 제조방법
CN120960132A (zh) 一种莫匹罗星软膏的药物组合物及其制备方法
Muthukumar Chapter-6 Solid Dispersion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180426

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180731

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20180731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180926

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181219